Thesedifferent classes of drugs inhibit ER function, but they take distinct routes, meaningthat resistance to one type of drug does not necessarily render other classes ofcompounds redundant and as such, different endocrine agents are used sequentially forthe treatment of ER+ breast cancer. This evidence concerns the gene ESR1 and breast cancer.